Blue Bird Corporation is a compelling investment due to its focus on electric school buses and attractive stock valuation despite recent performance setbacks. Read more here.

Blue Bird Corporation (BLBD) recently announced fiscal Q1 results, beating top and bottom-line expectations. While the ...

I mean, Blue Bird is clearly having longer-term tailwinds from the end market today while at the same time, its marginality is likely to stay elevated thanks to a better revenue mix in the future ...

The transaction agreement unreasonably limits competing transactions for bluebird by imposing a significant penalty if bluebird accepts a competing bid. We are investigating the conduct of bluebird's ...

93.59% of the stock is owned by institutional investors. Blue Bird Corporation, together with its subsidiaries, designs, engineers, manufactures, and sells school buses in the United States ...

Blue Bird Corporation (NASDAQ:BLBD), a leading manufacturer of school buses, has been making significant strides in the electric vehicle (EV) market while improving its operational efficiency.

Baird analyst Jack Allen downgraded Bluebird Bio (BLUE) to Neutral from Outperform with a price target of $5, down from $54, after the company ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out ...

Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle and SK Capital Partners at a discount, ending ...